INDOCO2024-07-012024-09-30 INDOCO2024-07-012024-09-30 INDOCO2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member INDOCO2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member INDOCO2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member INDOCO2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member INDOCO2024-09-30 INDOCO2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDOCO2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2024-04-01 2025-03-31 2024-10-24 2024-10-14 INR Lakhs Half yearly 11:25:00 12:20:00 2024-10-24 2024-10-24 true Cash Flow Indirect Not applicable Single segment PHARMACEUTICALS 2024-07-01 2024-09-30 Unaudited Consolidated 4326600000.00 15600000.00 4342200000.00 942600000.00 391500000.00 33900000.00 928800000.00 178300000.00 288200000.00 1627300000.00 4390600000.00 -48400000.00 0.00 -48400000.00 33600000.00 18100000.00 51700000.00 0.00 -100100000.00 0.00 0.00 0.00 0.00 -100100000.00 -9900000.00 -110000000.00 -95700000.00 -4400000.00 -105600000.00 -4400000.00 184400000.00 2 -1.09 -1.08 0.00 0.00 -1.09 -1.08 1. The unaudited Consolidated Results for the Quarter and Half Year ended 30th September, 2024 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 24th October, 2024. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales & Qtr ended Qtr ended Qtr ended Half year ended Half year ended Year ended Income from 30.09.2024 30.06.2024 30.09.2023 30.09.2024 30.09.2023 31.03.2024 Operations (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) India 29016 25675 26057 54692 49474 96758 Outside India 14050 16754 21301 30803 39565 82064 ---------------------------------------------------------------------------------------------------------- 43066 42429 47358 85495 89039 178822 ===================================================== 5. The Consolidated Financial Results includes the results of the following Companies Name of theCompany % of shareholding Consolidated as Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech S R O 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Ltd 100.00 Subsidiary FPP Holding Company , LLC 85.00 Subsidiary 6. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30.September, 2024 Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 8641600000.00 25800000.00 8667400000.00 2005000000.00 753700000.00 24100000.00 1901400000.00 321400000.00 563500000.00 3077100000.00 8646200000.00 21200000.00 0.00 21200000.00 81700000.00 21500000.00 103200000.00 0.00 -82000000.00 0.00 0.00 0.00 0.00 -82000000.00 -10800000.00 -92800000.00 -69400000.00 -12600000.00 -80200000.00 -12600000.00 184400000.00 2 -0.89 -0.89 0.00 0.00 -0.89 -0.89 OTHER EXPENSES 1474600000.00 RESEARCH & DEVELOPMENT EXPENSE 152700000.00 OTHER EXPENSES 2677500000.00 RESEARCH & DEVELOPMENT EXPENSE 399600000.00 -6600000.00 7972700000.00 2295100000.00 0.00 215200000.00 1297700000.00 352200000.00 0.00 0.00 14600000.00 0.00 32300000.00 69600000.00 116500000.00 0.00 1301500000.00 13550900000.00 3827200000.00 126000000.00 3819100000.00 181800000.00 109500000.00 15100000.00 27700000.00 4279200000.00 88200000.00 2152800000.00 10347400000.00 23898300000.00 184400000.00 10710900000.00 10895300000.00 10888700000.00 4429100000.00 51200000.00 4480300000.00 310800000.00 136400000.00 74200000.00 5001700000.00 3915000000.00 2414500000.00 1044400000.00 7373900000.00 201600000.00 432400000.00 8007900000.00 13009600000.00 23898300000.00 318500000.00 -296600000.00 185900000.00 0.00 -616500000.00 -3400000.00 -3500000.00 41700000.00 0.00 881400000.00 0.00 56900000.00 600000.00 563500000.00 0.00 -51200000.00 -32100000.00 123900000.00 12300000.00 61300000.00 0.00 3400000.00 14800000.00 0.00 0.00 0.00 0.00 -4000000.00 0.00 1250100000.00 1271300000.00 0.00 0.00 0.00 152300000.00 0.00 1119000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20500000.00 2230900000.00 0.00 53600000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3300000.00 0.00 -8500000.00 0.00 -2269200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1103300000.00 -531100000.00 23000000.00 0.00 127300000.00 300700000.00 0.00 0.00 1183400000.00 33200000.00 0.00 33200000.00 148600000.00 181800000.00 Items that will not be reclassified to profit and loss -3000000.00 Items that will not be reclassified to profit and loss -6000000.00 -3000000.00 -6000000.00 -800000.00 -1500000.00 Items that may be reclassified to profit & loss -9600000.00 Items that may be reclassified to profit & loss -8200000.00 -9600000.00 -8200000.00 -1900000.00 -1900000.00